Daclizumab - CAS 152923-56-3
Catalog number: 152923-56-3
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Others (Nonspecific immune stimulation)
Anti-CD25 (IL-2 receptor α‑chain) antibody; A humanized mAb of the human IgG1 isotype that binds specifically to the Tac epitope on the α-subunit (CD25) of the IL-2R; Phase I–II
Brife Description:
Anti-CD25 (IL-2 receptor α‑chain) antibody; A humanized mAb of the human IgG1 isotype that binds specifically to the Tac epitope on the α-subunit (CD25) of the IL-2R; Phase I–II
BIIB-019; DAC HYP; Dacliximab; Daclizumab high-yield process; Daclizumab HYP; HAT antibody; Humanised anti-Tac antibody; R35; RO 247375; SMART anti-Tac antibody; Zenapax; Zinbryta
Quality Standard:
Current Developer:
AbbVie; Biogen; PDL BioPharma
1.Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials.
Rashidi A1, DiPersio JF2, Sandmaier BM3, Colditz GA4, Weisdorf DJ5. Biol Blood Marrow Transplant. 2016 Mar 10. pii: S1083-8791(16)00150-6. doi: 10.1016/j.bbmt.2016.02.021. [Epub ahead of print]
Despite extensive research in the last few decades, progress in treatment of acute graft-versus-host disease (aGVHD), a common complication of allogeneic hematopoietic cell transplantation (HCT), has been limited and steroids continue to be the standard frontline treatment. Randomized clinical trials (RCTs) have failed to find a beneficial effect of escalating immunosuppression using additional agents. Considering the small number of RCTs, limited sample sizes, and frequent early termination because of anticipated futility, we conducted a systematic review and an aggregate data meta-analysis to explore whether a true efficacy signal has been missed because of the limitations of individual RCTs. Seven reports met our inclusion criteria. The control arm in all studies was 2 mg/kg/day prednisone (or equivalent). The additional agent(s) used in the experimental arm(s) were higher-dose steroids, antithymocyte globulin, infliximab, anti-interleukin-2 receptor antibody (daclizumab and BT563), CD5-specific immunotoxin, and mycophenolate mofetil.
2.Induction Therapy in Lung Transplantation? A frustrating message of persisting uncertainty.
Corris PA1. Am J Transplant. 2016 Mar 14. doi: 10.1111/ajt.13787. [Epub ahead of print]
The strategies and agents used to deliver induction therapy to lung transplant recipients typically mirror those used in other solid organ transplant recipients. Polyclonal antithymocyte globulin (ATG), antilymphocyte globulin (ALG) and monoclonal (OKT3) T-cell depleting agents, interleukin two (IL-2) Receptor antagonists (basiliximab and daclizumab) have been used most commonly. More recently there has been interest in the use of alemtuzumab (Campath) induction which may allow reduced maintenance immunosuppression during the first year post transplant. The rationale behind the use of induction therapy is based on perceived benefits of a reduced risk of acute lung rejection early post transplantation, with improved long term outcomes as a result. Registry data from the International Society for Heart and Lung Transplantation (ISHLT) demonstrates that induction appears to reduce acute rejection and have a small benefit in freedom from bronchiolitis obliterans (BOS)and long-term survival.
3.Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination.
Lin YC1, Winokur P1, Blake A1, Wu T1, Manischewitz J1, King LR1, Romm E1, Golding H1, Bielekova B1. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(1):e196. doi: 10.1212/NXI.0000000000000196. eCollection 2016.
OBJECTIVE: The purpose of this study was to assess the potential immunosuppressive role of daclizumab, a humanized monoclonal antibody against the α chain of the interleukin 2 receptor, in vivo, by comparing immune responses to the 2013 seasonal influenza vaccination between patients with multiple sclerosis (MS) on long-term daclizumab therapy and controls.
4.Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis.
Steinman L1, Zamvil SS. Curr Opin Neurol. 2016 Mar 29. [Epub ahead of print]
PURPOSE OF REVIEW: The review discusses future directions in research on multiple sclerosis and neuromyelitis optica, as long-held beliefs about these diseases are undermined with data from recent clinical trials.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Others (Nonspecific immune stimulation) Products

CAS 50-18-0 Cyclophosphamide

(CAS: 50-18-0)

Low-dose preferentially deplets Treg cells; An alkylating agent of the nitrogen mustard type with antineoplastic and immunosuppressive activities; Phase I–II

Denileukin diftitox
(CAS: 173146-27-5)

Recombinant IL‑2–diphtheria toxin conjugate; It works by interfering with the growth of cancer cells, which results in the death of the cells; Phase I–II

CAS 152923-56-3 Daclizumab

(CAS: 152923-56-3)

Anti-CD25 (IL-2 receptor α‑chain) antibody; A humanized mAb of the human IgG1 isotype that binds specifically to the Tac epitope on the α-subunit (CD25) of the ...


Recombinant human IL‑2; Interleukin-2 is a secreted cytokine, also called IL-2. Aldesleukin (IL-2 made in the laboratory) is being used as a biological response...


Recombinant human IFNα; A type I interferon consisting of 165 amino acid residues with lysine in position 23. It is used extensively as an antiviral or antineop...

Chemical Structure

CAS 152923-56-3 Daclizumab

Quick Inquiry

Verification code

Featured Items